transmembrane protein 63BGenealiases: C6orf110 · DEE118 · hTMEM63B
Q-omics provides the consensus-scored TMEM63B profile across patient tissues and cancer cell-line models. TMEM63B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM63B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TMEM63B protein abundance shows 28,088 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where TMEM63B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM63B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM63B survival associations across molecular data types. TMEM63B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM63B RNA expression–survival associations across cancer types. High TMEM63B expression shows unfavorable associations in ACC, BRCA, MESO, HNSC, SARC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM63B RNA expression.
This table summarizes TMEM63B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM63B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM63B shows lower tumor expression in LUAD and higher tumor expression in HNSC, KIRC, KIRP, THCA and BRCA. The HNSC box plot shows higher TMEM63B RNA expression in tumor versus normal tissue (log2 FC = +1.138, t-test p < 0.001).
This table shows molecular features associated with TMEM63B in patient tissues and cancer cell lines. In patient samples, TMEM63B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM63B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
